Xenon Pharmaceuticals Inc. (XENE) P/E Ratio History
Deep ValueTrading at -13.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2014–2015
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Xenon Pharmaceuticals Inc. (XENE) trades at a price-to-earnings ratio of -13.7x, with a stock price of $59.74 and trailing twelve-month earnings per share of $-4.39.
The current P/E is 121% below its 5-year average of 63.9x. Over the past five years, XENE's P/E has ranged from a low of 32.1x to a high of 95.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, XENE trades at a 160% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, XENE trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XENE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
XENE Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
XENE P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.1 | - | +68% | |
| $7B | 10.9Lowest | - | +264% | |
| $6B | 49.5 | - | +2886%Best | |
| $444B | 106.1 | - | -1% | |
| $297B | 21.6 | 1.41Best | +22% | |
| $613B | 23.1 | 1.55 | +91% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
XENE Historical P/E Data (2014–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q1 | - | $16.86 | $0.18 | 95.8x | +50% |
| FY2014 Q4 | Dec 31 2014 | $19.75 | $0.62 | 32.1x | -50% |
Average P/E for displayed period: 63.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XENE — Frequently Asked Questions
Quick answers to the most common questions about buying XENE stock.
What is XENE's P/E ratio?
Xenon Pharmaceuticals Inc. (XENE) trailing twelve-month P/E ratio is -13.7x, based on TTM diluted EPS of $-4.39. The 5-year average P/E is 63.9x and the historical range spans 32.1x to 95.8x.
Is XENE stock overvalued or undervalued?
XENE trades at -13.7x P/E, below its 5-year average of 63.9x. At the 0th percentile of its historical range (32.1x–95.8x), the stock is priced at a discount to its own history.
Is XENE stock expensive?
No, XENE is not expensive on a historical basis. The current P/E of -13.7x is below the 5-year average of 63.9x and sits at the 0th percentile of its valuation range.
What is XENE's historical P/E range?
Over the past 5 years, XENE's P/E ratio has ranged from 32.1x to 95.8x, with a median of 95.8x and an average of 63.9x. The current P/E of -13.7x places the stock at the 0th percentile of this range. Full historical data spans 2014–2015.
How does XENE's P/E compare to the S&P 500?
XENE trades at -13.7x P/E versus the S&P 500 median of 25.3x. The 154% discount to the market suggests lower growth expectations or perceived higher risk.
How does XENE's valuation compare to Healthcare peers?
Xenon Pharmaceuticals Inc. P/E of -13.7x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is XENE's PEG ratio?
XENE PEG ratio is N/A, based on a P/E of -13.7x and EPS growth of -44.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is XENE's earnings yield?
XENE earnings yield is N/A, the inverse of its -13.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.